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Abstract
Background: Membrane proteins regulate a diversity of physiological processes and are the most successful
class of targets in drug discovery. However, the number of targets adequately explored in chemical space
and the limited resources available for screening are significant problems shared by drug-discovery centers
and small laboratories. Therefore, a low-cost and universally applicable screen for membrane protein trafficking
was developed.
Results: This high-throughput screen (HTS), termed IRFAP-HTS, utilizes the recently described MarsCy1-fluorogen
activating protein and the near-infrared and membrane impermeant fluorogen SCi1. The cell surface expression of
MarsCy1 epitope-tagged receptors can be visualized by simple addition of SCi1. User-friendly, rapid, and quantitative
detection occurs on a standard infrared western-blotting scanner. The reliability and robustness of IRFAP-HTS was
validated by confirming human vasopressin-2 receptor and dopamine receptor-2 trafficking in response to agonist or
antagonist. The IRFAP-HTS screen was deployed against the leucine-rich G protein-coupled receptor-5 (Lgr5). Lgr5 is
expressed in stem cells, modulates Wnt/ß-catenin signaling, and is therefore a promising drug target. However, small
molecule modulators have yet to be reported. The constitutive internalization of Lgr5 appears to be one primary mode
through which its function is regulated. Therefore, IRFAP-HTS was utilized to screen 11,258 FDA-approved and drug-like
small molecules for those that antagonize Lgr5 internalization. Glucocorticoids were found to potently increase Lgr5
expression at the plasma membrane.
Conclusion: The IRFAP-HTS platform provides a versatile solution for screening more targets with fewer resources.
Using only a standard western-blotting scanner, we were able to screen 5,000 compounds per hour in a robust and
quantitative assay. Multi-purposing standardly available laboratory equipment eliminates the need for idiosyncratic
and more expensive high-content imaging systems. The modular and user-friendly IRFAP-HTS is a significant departure
from current screening platforms. Small laboratories will have unprecedented access to a robust and reliable screening
platform and will no longer be limited by the esoteric nature of assay development, data acquisition, and post-
screening analysis. The discovery of glucocorticoids as modulators for Lgr5 trafficking confirms that IRFAP-HTS
can accelerate drug-discovery and drug-repurposing for even the most obscure targets.
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Background
The advent of high-throughput screening (HTS) has
enabled successful unbiased drug-discovery and fostered
the development of novel therapies [1]. Arguably the
most fruitful targets in HTS platforms have been mem-
brane proteins, which comprise 22 % of the proteins
encoded by the genome and are targeted by 60 % of the
approved drugs available today. Incredibly, almost half of
these drugs are directed at the rhodopsin-like class I G
protein-coupled receptor (GPCR) superfamily [2]. Many
of these receptors have underlying roles in a myriad of
diseases, including cancer, heart disease, diabetes, and
mental illness. Therefore, membrane proteins represent
a gold mine of targets that must be screened in order to
fully exploit their rich therapeutic potential.
For instance, the expression of the leucine-rich G
protein-coupled receptor-5 (Lgr5) was recently shown to
identify stem cells of the intestine [3]. More recent
evidence has demonstrated that adult tissue-specific
stem cells of the stomach [4], hair follicle [5], and mam-
mary gland [6, 7], can be identified solely through ex-
pression of Lgr5. The Lgr5-expressing stem cell is a
critical contributor to tissue maintenance, and may also
be the cell of origin in gastrointestinal cancers [8, 9].
Lgr5 is a GPCR whose biochemical and cellular proper-
ties have evaded investigators since its discovery in 1998
[10, 11]. Therefore, Lgr5 is an exciting membrane pro-
tein target for which small molecule modulators are
unfortunately lacking. Previously, we have shown that
Lgr5 constitutively internalizes from the plasma mem-
brane and retrograde traffics to the trans-Golgi network
[12]. Inhibiting this internalization resulted in the forma-
tion of ‘cytonemes’, which are ultra-long actin-rich
signaling filopodia capable of scaffolding cell signaling at
a distance [13, 14]. Together, these data suggest that
internalization and trafficking of Lgr5 may be critical
for fine-tuning its function. Therefore, small molecule
modulators of Lgr5 trafficking may prove to be a
powerful strategy for pharmacologically modulating
stem cell activity.
High-throughput screening platforms for plasma mem-
brane receptors have had success due to reliable cell-
based systems for monitoring a diversity of downstream
messengers [15], such as cAMP, Ca2+ mobilization, and
Rho GTPase activation, or translocation of adaptor mole-
cules after activation such as β-arrestin [16]. However, in
most cases, these assays are highly idiosyncratic and
consequently require specialized protocol development.
HTS becomes especially challenging for those receptors
that are biologically rich but have non-canonical signaling
or remain uncharacterized, such as Lgr5. Whereas recep-
tor signaling is specialized, all classes of plasma membrane
receptors are synthesized in the endoplasmic reticulum,
before their targeting to the cell surface. Thus, plasma
membrane trafficking is the single universal feature of
membrane receptor protein regulation. Reasons that HTS
trafficking screens are not more often utilized include a
lack of reagent universality, expensive imaging equipment,
and confounding background fluorescence that in many
instances requires sophisticated de-convolution algo-
rithms to identify subpopulations of membrane proteins.
Our solution relies upon a new class of genetically
encoded fluorogen activating proteins (FAPs) that
immuno-react with and induce the fluorescence of
spectrally tunable and weakly fluorescent compounds
(fluorogens) [17]. The synthesis of a novel near-
infrared FAP (MarsCy1):Fluorogen (SCi1) and its ver-
satile use for in vivo imaging of tumors was recently
described [18]. Herein, we pair MarsCy1 with a low
cost infrared (IR) western-blotting scanner for simul-
taneous multi-plate analysis of receptor trafficking in
a high-throughput system that we term IRFAP-HTS.
Fluorogen fluorescence is increased up to 20,000-fold
when receptors genetically fused to the FAP bind to
the fluorogen. Real-time monitoring of FAP-tagged
membrane protein trafficking occurs by simple
addition of fluorogen without the need for reagent
washes or highly-automated equipment [17, 19]. We
validated IRFAP-HTS with GPCRs of well-known
pharmacology and then confirmed its utility by
screening and identifying small molecule modulators
of Lgr5 trafficking.
Results
Validating a sensor for visualizing cell surface expression
of membrane proteins
Quantifying receptor expression using affordable multi-
purpose equipment available in most labs would be
particularly advantageous to small academic laboratories.
The excitation and emission of the MarsCy1/SCi1 pair
(Ex/Em: 703 nm/733 nm) occurs in a range suitable
for use on many IR-western blotting scanners and is
easily resolved from the visible spectrum, which is often
filled by other reporters (i.e. EGFP and RFP). The feasibil-
ity of the system was first tested by fusing an N-terminal
Hemagglutinin (HA)-MarsCy1-FAP to Lgr5-EGFP (Mars
Cy1-Lgr5-EGFP). The membrane permeant near-IR
fluorogen (SC1) stained MarsCy1-Lgr5-EGFP and verified
the expected localization of Lgr5 in intracellular vesicles
(Additional file 1: Figure S1). The membrane impermeant
variant of SC1 (SCi1) was next tested for its ability to
confer cell-surface labeling of membrane proteins. SCi1
enabled robust cell surface labeling of a MarsCy1-CD80
transmembrane fused protein, with undetectable intracel-
lular staining (Fig. 1a).
The ability for SCi1 to label cell surface MarsCy1-tagged
receptors and permit real-time imaging of trafficking was
evaluated and directly compared to standard HA-
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immunolabeling. Cells expressing MarsCy1-Lgr5-EGFP
were co-pulsed with HA-antibody and SCi1 at 4 °C to
label the cell-surface pool of the receptor (Fig. 1b–d and
Additional file 2: Figure S2). In the absence of chase, cells
displayed low level Lgr5 surface expression, as revealed by
equivalent SCi1 and HA-immunoreactivity. This corre-
sponds with the previously described intracellular
localization of Lgr5 and is again revealed by native EGFP
fluorescence (Fig. 1c). Previous findings demonstrate that
Lgr5 constitutive internalization can be blocked by over-
expression of a dominant negative form of Dynamin I
(K44A) [12]. K44A expression robustly increased cell sur-
face staining by SCi1 and HA-antibody staining (Fig. 1c).
When cells were chased for 30 minutes at 37 °C, the cell
surface fraction of Lgr5 rapidly internalized into vesicles
(Fig. 1d). K44A significantly blunted this internalization
(Fig. 1d). Importantly, MarsCy1 fusion did not perturb
normal Lgr5 trafficking (Additional file 3: Figure S3 and
Additional file 4: Figure S4) and could be used in
combination with SCi1 to monitor the subcellular distri-
bution of Lgr5 and its internalization by confocal micros-
copy (Fig. 1).
Previously, we quantified receptor internalization by
HA-immunolabeling cells in a plate-format and scanning
on an IR western blotting scanner [12]. Therefore, we
directly compared HA-immunolabeling and Mars-
Cy1:SCi1 staining on cells expressing MarsCy1-Lgr5-
EGFP that were co-pulsed with SCi1 and HA-antibody
(800 nm). The entire 12-well plate was scanned on a
LiCOR-Odyssey® IR imaging system and quantified.
MarsCy1-Lgr5-EGFP cells weakly expressed Lgr5 on the
plasma membrane, whereas those cells co-transfected
with K44A demonstrated a robust increase in Lgr5 cell
surface expression. SCi1 and HA-800 perform similarly
in this assay and quantitatively confirm the confocal
imaging data analysis (Fig. 1e,f and Additional file 4:
Figure S4). We also generated a MarsCy1-fused human
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Fig. 1 Quantitative scanning of MarsCy1-tagged membrane proteins in a modular plate-based format. a Top: Cartoon depicting HA-FAP fused to the
N-terminus of the CD80 transmembrane domain. Bottom: Confocal imaging of FAP-CD80 transfected cells stained with SCi1. b Cartoon depicting
HA-FAP fused to the N-terminus of Lgr5 and EGFP fused to the C-terminus. c Confocal imaging of FAP-tagged Lgr5-EGFP transfected cells that were
co-labeled with SCi1 (magenta) and a primary HA-epitope antibody (Red, secondary retrieval – 568 nm) at 4 °C to block receptor internalization and
were chased in (d) for 30 minutes at 37 °C to allow constitutive internalization of Lgr5 (EGFP, green) (K44A, A dominant-negative Dynamin I mutant
that inhibits receptor endocytosis when over-expressed). e Infrared plate imaging of a 12-well plate (see Additional file 4: Figure S4 for entire plate and
time-course) with FAP-tagged Lgr5 pulsed with SCi1 and a primary HA-epitope antibody at 4 °C and then fixed. Non-permeabilized cells were scanned
on the plate at 700 nm (red, SCi1) and 800 nm (green, HA secondary retrieval-800 nm) (NT: non-transfected). f Integrated fluorescence intensity from
(e). g MarsCy1-tagged hV2R was transiently transfected in HEK cells on a 24-well plate and stimulated with vehicle (–AVP) or the V2R ligand AVP
[10 μM] for 1 hour. Cells were SCi1 stained, scanned, and quantified
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IR-scanning of MarsCy1:SCi1 enabled quantification of
prototypical agonist-induced GPCR internalization
(Fig. 1g). At steady-state, the V2R exhibits very little in-
ternalization [20]. MarsCy1 staining and live confocal
imaging confirmed this finding, verified that SCi1 is
membrane impermeant, and demonstrated that MarsCy1-
tagging can be used to visualize trafficking in living cells
in real-time (Additional file 5: Movie S1). Collectively,
these data demonstrated that MarsCy1-tagged GPCRs and
the membrane impermeant fluorogen SCi1 can be used to
quantifiably and reliably assess surface expression of
GPCRs.
Cell surface rescue of GPCRs
For MarsCy1:SCi1 to be a valid screening platform,
the assay must enable the robust quantification of re-
ceptor cell-surface expression in a high-throughput
multi-well plate format. Since small molecule modula-
tors of Lgr5 function have not been reported, we used
a prototypical GPCR with better characterized traffick-
ing and signaling modes to validate this system. Most
class 1 GPCRs possess a canonical ‘DRY’ motif at the
end of transmembrane-domain three which can
stabilize the receptor in an inactive state and is also
important in G protein-coupling (Fig. 2a) [21, 22].
Mutations to this domain contribute to disease by
resulting in constitutive activation and internalization
of the receptor [20, 23] in addition to misfolded recep-
tor that accumulates in the ER [24]. Therefore, we
tested if the MarsCy1:SCi1 system could be used to
identify small molecules that rescue surface expression
of a mutant GPCR with a known pharmacological pro-
file. We generated an N-terminally MarsCy1-tagged
wild-type human D2 dopamine receptor and a DRY to
AAY mutant D2R (DRY). Inclusion of an EYFP tag at
the D2R C-terminus, revealed by confocal microscopy
that wild-type human D2 dopamine receptor displayed
normal cell surface expression relative to the internal-
ized and intracellularly localized DRY mutant. As
expected, overnight treatment with the D2R antagon-
ist spiperone significantly rescued surface expression
of the DRY mutant (Fig. 2b).
SCi1 staining enabled robust visualization and quanti-
fication of plasma membrane surface rescue for the
DRY mutant receptor (Fig. 2c, d). This assay was then
scaled up to a 96-well plate format for screening
MarsCy1 DRY mutant expressing cells against six char-
acterized D2R antagonists. As expected, each antagon-
ist was able to partially rescue DRY mutant surface
expression (Fig. 2e, f ). Z’-factor analysis provides a
statistical measure of HTS robustness and reliability
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Fig. 2 Monitoring cell surface rescue of a mutant intracellularly mis-localized membrane protein. a Cartoon depicting HA-FAP fused to the N-terminus
of wild-type (WT) D2R or DRY-AAY (DRY) D2R and EYFP on the C-terminus. b Confocal imaging for EYFP-tagged WT-D2R or DRY-D2R treated with
vehicle (DMSO) or the D2R antagonist spiperone [10 μM]. c Infrared plate imaging for membrane impermeable SCi1 bound to FAP-tagged WT- or
DRY-D2R treated with DMSO or spiperone (S, 10 μM) overnight. d Quantification of triplicate experiments represented in panel (c) and normalized
relative to WT-D2R surface expression (* denotes significant difference by ANOVA and post hoc Tukey-analysis). e Small-scale dose-response screen of
overnight treatment with small molecule antagonists using quantitative infrared plate imaging (V, DMSO Vehicle; S, Spiperone; R, Risperidone;
Q, Quetiapine; O, Olanzapine; C, Clozapine. 10-10 (-10) M to 10-5 (-5) M). f Quantification of triplicate experiments of the representative image
in (e) and normalized to spiperone (S). g Infrared image of 10 μM spiperone DRY-D2R surface expression rescue for Z’-factor analysis. h
Quantification of panel (g) and calculation of a Z’-factor (* denotes significant difference by student’s unpaired t-test)
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platform [25]. A Z’-factor of 0.7 was calculated for
spiperone-mediated DRY surface expression in a 96-
well plate format. These data demonstrated that the
MarsCy1:SCi1 system can report on the cell surface
expression of GPCRs in a format amenable for HTS.
HTS for candidate small molecules that rescue Lgr5
surface expression
The MarsCy1:SCi1 system was then tested for its utility
as a screening platform. Lgr5 was chosen as a prime
candidate due to its unique expression in stem cells, its
well-documented constitutive internalization properties
[12, 26], and its lack of reported small molecule
modulators. Before the Lgr5 screen was initiated, the
MarsCy1:SCi1 system was first reformatted and tested in
a 384-well system to increase throughput to 5,000 wells/
hour. Z’-factors for the assay were calculated with either
K44A overexpression or comparison to a cell line ex-
pressing an Lg5/V2R fusion previously shown to have
increased surface expression (MarsCy1-Lgr5/V2R-EGFP)
[12]. Both comparisons demonstrated that the 384-well
format provides an excellent screening platform that we
have termed IRFAP-HTS (Z’-factor = 0.84 and Z’-factor
= 0.67) (Fig. 3a-d). A total of 11,258 compounds from
five libraries of diverse chemical space were screened
using IRFAP-HTS. These libraries target kinases,



























































Fig. 3 Screening for small molecule modulators of Lgr5 surface expression. a Infrared image of a stable U2OS cell line expressing MarsCy1-Lgr5 in a
384-well plate without (–K44A) and with transient transfection (+K44A) of Dynamin I K44A (NT, parental U2OS cells). b Quantification of (a) and Z’-factor
analysis. c Infrared image of a stable U2OS cell lines expressing MarsCy1-Lgr5 compared to MarsCy1-Lgr5/V2R-tail (NT, parental U2OS cells).
d Quantification of (c) and Z’-factor analysis. e A total of 91 hits were cherry picked and incubated overnight at 37 °C on stable MarsCy1-Lgr5-
EGFP cells. Black bar, wild-type Lgr5; Hatched bar, +K44A control; Pink bar, autofluorescent compounds (violet, yellow, blue, and green bars as
in 3f). Hits were measured against the ± 1, 2, 3 standard deviations from wild-type DMSO mean (green, blue, and red lines). Each compound is
described according to plate ID, library name (JH, John’s Hopkins; PT, Prestwick; KG, Kinase Gold), common drug name, and position on the
secondary screening plate. f Synthetic glucocorticoid receptor agonists from (e) were purchased, in addition to dexamethasone, and screened
in a dose-response assay. g and h Spiperone and glucocorticoids, respectively, increase plasma membrane expression of D2R-DRY and Lgr5
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GPCRs, and FDA-approved clinically effective drugs and
included John’s Hopkins Clinical Compound Library
(1,518 compounds, 60 hits, 4.0 % hit-rate, Additional
file 6: File S1) [27], Kinase Gold Library (3,519 com-
pounds, 29 hits, 0.8 % hit-rate, Additional file 7: File
S2), Prestwick Library (1,120 compounds, 129 hits,
11.5 % hit-rate, Additional file 8: File S3), SigmaKinase
(101 compounds, 1 hit, 0.9 % hit-rate, Additional file 9:
File S4), and ActProb5k (5,000 compounds, 51 hits,
1.0 % hit rate, Additional file 10: File S5).
We found 270 total hits that increased Lgr5 surface
expression, equating to a primary screen hit rate of
2.4 %. We cherry-picked 91 of these hits and performed
a secondary screen at 20 μM and 0.2 μM and found that
25 % of these were reproducible at 20 μM (Fig. 3e and
Additional file 11: Figure S5). Some hits were also
discounted due to their fluorescent properties overlap-
ping with the same spectrum as the IR detector. Among
the most promising hits, we were intrigued by the
discovery of several glucocorticoids, some of which were
hits across multiple libraries. Each of the glucocorticoids
potently and significantly increased Lgr5 surface expres-
sion (Fig. 3f ). Other hits, while reproducible, were
either beyond the scope of this study or have limited
availability for further testing outside of in-house
synthesis. The specificity of glucocorticoids was deter-
mined in a counter-screen against the D2R receptor
using MarsCy1-DRY expressing cells. The membrane
permeant antagonist spiperone robustly rescues DRY
surface expression but has no effect on Lgr5 (Fig. 3g).
In contrast, glucocorticoids increase Lgr5 surface
expression while displaying no activity toward D2R
DRY (Fig. 3h and Table 1). We tested dexamethasone
for direct binding to Lgr5. Dexamethasone did not bind
to Lgr5 with high-affinity (Additional file 12: Figure
S6). This implies that Lgr5 surface expression might be
indirectly regulated by glucocorticoid receptor signal-
ing. These data demonstrate that the IRFAP-HTS is a
user-friendly, modular, and rapidly deployable screen-
ing platform.
Discussion
Historically, and as a result of reliance on state-of-the-art
instrument technologies, screening platforms have re-
quired significant upfront capital investment in robotics,
assay-specific detection systems, and workspace [28]. The
IRFAP-HTS platform described in this study instead en-
ables real-time HTS of membrane protein surface
expression in an easy-to-use, versatile, and rapidly deploy-
able format. The success of our platform lies in the ability
to robustly and precisely screen for membrane protein traf-
ficking with limited upfront investment. Overall, this is a
substantial departure from standard HTS platforms. In
summary, the IRFAP-HTS provides a system where a sin-
gle investigator in a small laboratory space can easily and
affordably screen their chosen target against modestly sized
compound libraries (10,000 compounds) in a single week.
A combination of several desirable features enabled
realization of this technology. In contrast to other HTS
platforms, the FAP-based screen only requires access to
standard cell culture facilities, low-cost manual pipetting
systems, and a highly-versatile IR western-blotting scan-
ner commonly available to most basic science labs. In
this study, we were able to utilize 12-, 24-, 96-, 384-, and
single-well formats with little to no change in experi-
mental workflow. This enables acquisition of close to
5,000 data points in 1 hour, since six 384-well plates can
be processed in parallel within approximately 30 minutes.
The images generated in our assay encompass the plate
in its entirety and enables immediate and visually quali-
tative hit-analysis. This mitigates the need for extensive
data analysis, de-convolution, and software investment.
Our assay has essentially no, to at most, very low back-
ground due to the spectral characteristics of the near-IR
region in cell-based systems. MarsCy1-tagged protein
targets are easily generated using common molecular
biological techniques and in the multitude of proteins
tested have not significantly impacted normal trafficking.
The specificity of MarsCy1-induced SCi1 fluorescence is
due to the very high-affinity antibody-based fluorescence
enhancement. This chemistry enables scanning within
Table 1 Small molecules
Drug CAS No. MW Supplier Cat# Solvent Stock
DEX 50-02-2 392.46 Sigma D1756 100 % EtOH 10 mM
DEX dipropionate 55541-30-5 504.59 TimTec ST024761 100 % EtOH 10 mM
DEX 21-acetate 1177-87-3 434.5 Sigma D1881 100 % EtOH 10 mM
Beclomethasone dipropionate 9/8/5534 521.04 Sigma B3022 100 % EtOH 10 mM
Betamethasone 378-44-9 392.46 TRC B327000 100 % EtOH 10 mM
Betamethasone 17,21-dipropionate 5593-20-4 504.59 Sigma B1152 100 % EtOH 10 mM
Prednisolone 50-24-8 360.44 Sigma P6004 100 % EtOH 10 mM
Prednisolone 21-acetate 52-21-1 402.48 Sigma P8650 100 % EtOH 10 mM
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minutes of SCi1 addition without the need for washing
unbound material. This obviates the need for additional
liquid handling and plate-washers and thereby reduces
cell loss that can accompany extensive handling. In
addition, MarsCy1-SCi1 enables co-screening with other
fluorescent assay reporters, such as those far removed
from the IR spectrum (Additional file 13: Figure S7).
Proof-of-principle for the IRFAP-HTS was achieved by
focusing on three different applications for membrane
proteins. This included agonist-induced internalization
of the V2R, antagonist drug rescue of the mutant D2R,
and drug discovery for the small-molecule-orphan Lgr5.
These data demonstrated that the IRFAP-assay can be
utilized in agonist or antagonist mode without any
modifications to the platform. For HTS, we chose Lgr5
as a prototype since we are interested in its unique traf-
ficking properties, its role in stem cell biology and can-
cer, and its history as a difficult target to study. The
proposed Lgr5 ligands, Rspondin [29–31] and Norrin
[32], do not activate classical G protein or ß-arrestin
dependent signaling pathways, making standard screen-
ing assays difficult. This is despite the conservation of
key signaling determinants for typical GPCR signal
transduction and a fully functional ß-arrestin transloca-
tion domain [33]. Surprisingly, the IRFAP-HTS system
identified synthetic glucocorticoid receptor (GR) ago-
nists as potent modulators of Lgr5 trafficking.
Glucocorticoids exert many effects on tissue develop-
ment and maturation. Work from Florence Moog’s lab
in the 1950s demonstrated that glucocorticoids drive
proper maturation of the intestinal epithelium [34, 35].
Moog’s work enabled a series of investigations that fur-
ther outlined roles for glucocorticoids in the maturation
of the intestine. These studies confirmed Moog’s original
observations, identified the window of glucocorticoid re-
sponsiveness, and first suggested that cells within the
crypt might be the primary target in the epithelium [36–
40]. Interestingly, GR agonists act on intestinal epithelial
cells to inhibit proliferation, promote morphological
changes, and restructure the trans-Golgi network (TGN)
[41]. Therefore, in the context of our previous findings
[12], the GR-mediated restructuring of the TGN network
may provide one mechanism whereby the TGN-localized
Lgr5 can more efficiently traffic to the plasma mem-
brane. These data all point to an unexpected but import-
ant link between GRs and Lgr5. The clinical and
therapeutic implications of this finding will be the sub-
ject of future research.
Repurposing drugs is a viable alternative to deep high-
throughput screening of millions of combinatorial com-
pounds with unknown pharmacological profiles [27]. In
fact, directed screens against FDA-approved compounds
have been successful in defining new activity for many
commonly used and clinically relevant compounds [42].
Many of these hits can be used as a scaffold for
chemical evolution to further refine their activity pro-
file and efficacy [43]. Therefore, using IRFAP-HTS,
small academic laboratories can now institute drug-
repurposing programs targeted against their mem-
brane protein of interest.
Conclusions
A major objective of the post-genomic era has been to iden-
tify molecular targets of disease and develop new modes of
pharmacological intervention. Therefore, we have developed
a versatile IRFAP-HTS for membrane protein trafficking so
that any lab can easily screen approximately 10,000 small
molecules per week and have a high-probability of finding a
significant hit. This study demonstrates the viability of this
system by using NIH-procured libraries and affordably
priced commercial libraries. Using IRFAP-HTS, even the
smallest of laboratories can make a minimal investment of
$5,000 to obtain and screen approximately 1,500 FDA-
approved compounds [27] against any user-defined mem-
brane protein. We expect that the IRFAP-HTS will trans-
form drug-discovery into an open-source pursuit within
reach of all basic science and clinical research laboratories
and, for the first time, provide a platform for the synergistic
exploration of disease targets in the public domain.
Methods
Biological constructs
The described MarsCy1 sequence [18] was PCR-
amplified and overlap-exchanged into the N-terminus
of a human Lgr5 C-terminal EGFP fusion previously
described. To confer appropriate trafficking MarsCy1
was inserted immediately following the 5’-signal se-
quence of Lgr5. Human D2R and V2R lack cleavable
signal sequences due to the absence of a large extracel-
lular N-terminal domain. Therefore, to confer correct
ER transport and plasma membrane insertion for each
receptor, the signal sequence of Lgr5 was included on
the MarsCy1-tagged D2R and V2R. A MarsCy1-CD80
fusion is described in Zhang et al. [18].
MarsCy1 staining
SC1 and SCi1 were synthesized according to Zhang et
al. [18] and reconstituted in ethanol with 5 % acetic acid
at 200 μM or 78 μM, respectively. Live or fixed cells
were incubated with 200 nM SC1 or 20 nM SCi1 for
5 minutes and then imaged. No washing was performed
unless indicated.
Antibody staining
Live cells were pulse-labeled with HA-antibody (1:500
dilution in staining media) as previously described.
Following a 45-minute pulse on ice, cells were washed
and then fixed or chased. A secondary Donkey-anti-
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Mouse-800 nm (LiCOR®, cat#926-32212, Lincoln, NE) or
Goat-anti-Mouse-568 (LifeTechnologies, cat# A-11004,
Carlsbad, CA) was used for IR scanning or confocal
microscopy, respectively.
MarsCy1 confocal imaging
Confocal imaging for SC1 and EGFP was performed on
a Zeiss LSM510 confocal microscope (Carl Zeiss
Microscopy, Germany). For three-color imaging of SCi1,
EGFP, and HA immunolabeling (568 nm) a Zeiss
LSM780 confocal microscope was used (Carl Zeiss Mi-
croscopy, Germany).
MarsCy1 IR scanning
A LI-COR Odyssey® (LI-COR Biosciences, Lincoln, NE)
system was used for scanning MarsCy1 tagged receptors
stained with SCi1 or SC1 in the 700 nm channel. Focal
offsets were adjusted accordingly to match the focal
plane of the plate. For cells stained with SCi1 and immu-
nolabeled for HA (800 nm), plates were scanned at
700 nm and 800 nm, respectively.
IRFAP-HTS protocols
A detailed description of all HTS protocols, the primary
data generated, mining algorithms for processing hits,
and the library descriptions can be found as Microsoft
Excel worksheets (Microsoft Office 2011, Microsoft
Corporation, Redman, WA) in Additional file 6: File S1,
Additional file 7: File S2, Additional file 8: File S3,
Additional file 9: File S4 and Additional file 10: File S5.
Briefly, MarsCy1-tagged cell lines were incubated with
drugs overnight in 384-well plates, and then fixed and
stained with SCi1, or stained with SCi1 and scanned live,
as indicated. Up to six-plates were scanned at 700 nm
using a LI-COR Odyssey® in approximately 30 minutes.
Data were exported and merged with the library key
files (available at https://web.duke.edu/gpcr-assay/) in
Microsoft Access (Microsoft Office 2011, Microsoft
Corporation, Redman, WA). Merged files were then
mined in Excel.
Chemical cataloguing
Top hits were purchased and freshly made for further
evaluation. These include those listed in Table 1.
Statistical analysis
Statistical analysis was performed in GraphPad Prism
(GraphPad Software, Inc., La Jolla, CA).
Additional files
Additional file 1: Figure S1. Testing MarsCy1-Lgr5 expression and activity
toward SC1. (a) Live HEK cells stained with SC (30 min at 0. 2 μM) and imaged
at 488 and 633 nm with a confocal microscope. No staining was observed.
(b–d) HEK cells were transiently transfected with MarsCy1-Lgr5 and imaged at
488 and 633 nm by confocal microscopy. (b) SC unstained control. (c) Live
HEK cells stained with SC (0. 2 μM) for 30 minutes without a washout. (d) Live
HEK cells stained with SC (0. 2 μM) for 30 minutes, washed, fixed, and
imaged. (e) LI-COR imaging of non-transfected or MarsCy1-Lgr5
transfected cells that were stained with SC with or without washing.
The integrated intensity is also shown. (f) U2OS clones stably expressing
MarsCy1-Lgr5 (duplicates (e/f)) compared to parenteral cells display varying
degrees of MarsCy1 induced SC activity. Average integrated intensity is
shown. (PDF 1545 kb)
Additional file 2: Figure S2. Single color controls for multi-color
confocal microscopy. MarsCy1-Lgr5-EGFP was stained with SCi1 and HA-
568 or unstained (EGFP). Spectral gating and laser power was set on a
LSM-780 to eliminate channel overlap. (PDF 5943 kb)
Additional file 3: Figure S3. MarsCy1-tagged Lgr5 retains normal
trafficking behavior. HEKT cells were transiently transfected with MarsCy1-
Lgr5-EGFP. (a) Confocal images of cells pulse labeled with HA-antibody
(568) for 45 minutes on ice and chased for 0, 30, or 120 minutes. (Top:
3xHA-Lgr5-EGFP vs Bottom: Mars1-Lgr5-EGFP). (b) Same as (a) but with
overexpression of the endocytosis inhibitor dynamin K44A. (Red: 568 nm/
HA; Green: 488 nm/EGFP; Blue: 633 nm/Nuclear Dye. (PDF 20474 kb)
Additional file 4: Figure S4. MarsCy1-tagged Lgr5 retains normal
trafficking behavior and can be quantified on an infrared western
blotting imager. HEKT cells were transiently transfected with MarsCy1-
tagged Lgr5-EGFP on a 12-well plate. Cells were co-pulsed with SCi1
and HA-antibody on ice for 45 minutes and then chased for (a) 0, (b) 30,
or (c) 120 minutes and scanned on a LiCOR Odyssey for SCi1 (700 nm)
and HA (800 nm). (d) Quantification of (a–c). (PDF 4232 kb)
Additional file 5: Movie S1. MarsCy1-V2R live imaging. MarsCy1
tagged V2R was transiently expressed in HEK cells. SCi1 was added to
cell culture media. Cell membranes were fluorescent within 1 minute
and reached a peak at approximately 3.5 minutes, at which point the
time-lapse began. Images were acquired every 30 seconds for 15 minutes.
Note that internalization of unstimulated V2R is not detected and that
SCi1 does not penetrate the plasma membrane. No washing was
performed since unbound SCi1 is only weakly fluorescent. (MOV 451 kb)
Additional file 6: File S1. John’s Hopkins Clinical Compound Library.
Lgr5 IRFAP-HTS results provided in a Microsoft Excel Spreadsheet with
three worksheets that include (Description) the experimental overview,
(Data) Raw and Analyzed data, (PivotTable) and a pivot table for data
mining and determination of hits. (XLS 1334 kb)
Additional file 7: File S2. Kinase Gold Library. Lgr5 IRFAP-HTS results
provided in a Microsoft Excel Spreadsheet with three worksheets that
include: (Description) the experimental overview, (Data) Raw and Analyzed
data, (PivotTable) and a pivot table for data mining and determination of
hits. (XLS 2999 kb)
Additional file 8: File S3. Prestwick Library. Lgr5 IRFAP-HTS results
provided in a Microsoft Excel Spreadsheet with three worksheets that
include: (Description) the experimental overview, (Data) Raw and
Analyzed data, (PivotTable) and a pivot table for data mining and
determination of hits. (XLSX 344 kb)
Additional file 9: File S4. Sigma Kinase Library. Lgr5 IRFAP-HTS results
provided in a Microsoft Excel Spreadsheet with three worksheets that include:
(Description) the experimental overview, (Data) Raw and Analyzed data,
(PivotTable) and a pivot table for data mining and determination of hits.
(XLS 218 kb)
Additional file 10: File S5. ActProb5K Library. Lgr5 IRFAP-HTS results
provided in a Microsoft Excel Spreadsheet with three worksheets that in-
clude: (Description) the experimental overview, (Data) Raw and Analyzed
data, (PivotTable) and a pivot table for data mining and determination of
hits. (XLSX 2266 kb)
Additional file 11: Figure S5. Rescreening of hits at 0.2 μM. Hits were
individually selected and incubated overnight at 0.2 μM overnight on stable
MarsCy1-Lgr5-EGFP cells in a 384-well plate. Black, WT Lgr5; Hatched bar,
+K44A control; Pink bar, reportedly autofluorescent compounds; violet,
yellow, blue, and green bars correspond to Fig. 1f tested GR agonists. JH,
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John’s Hopkins; PT, Preswick; KG, Kinase Gold. Each compound is described
according to plate ID, library name, common drug name, and position on
the secondary screening plate. KG lacks common names. (PDF 1088 kb)
Additional file 12: Figure S6. Dexamethasone does not directly bind
Lgr5. Membrane proteins were extracted from U2OS cells stably expressing
WT Lgr5, Lgr5/V2r, or control cells expressing human neurotensin-2 (NTR2).
(h + c) Lgr5 extracts were incubated with 10 μM dexamethasone (c: cold)
washed and then incubated with 3H-dexamethasone (h: hot). (hot) Lgr5
extracts were incubated with 10 μM 3H-dexamethasone. As a control NTR2
binding experiments were similarly performed with hot 10 nM 3H-
neurotensin or cold neurotensin. As expected, pre-incubation with
cold neurotensin reduces binding of hot ligand. Specific binding of
dexamethasone was not observed for Lgr5 or in the negative control
NTR2. (PDF 40 kb)
Additional file 13: Figure S7. Multi-color HTS of Lgr5 membrane
expression β-arrestin-2 translocation. Stable U2OS cells expressing
MarsCy1-Lgr5-V2R and β-arrestin-2-EGFP were screened against the
ActivProb library (plate 1 shown) and fixed with 4 % PFA. (a) Cells were
stained for SCi1 and imaged on an IR-western blotting scanner (700 nm).
(Column 1: U2OS parenteral line, Columns 2, 23, and 24: DMSO, Columns
3–22: Drug). (b) The plate was then imaged at 257.6× magnification on a
Zeiss AxioZoom Microscope. Eight images for each well were imaged
using automated ZenBlue software totaling 2,880 images in 20 minutes,
as previously published and termed ArrestinZoom. (Column 1 was not
imaged as it does not have GFP expression). (c) Box in (b) shown at 35 %
magnification and (d) asterisk denoted area in (c) shown at 100 %. No
hits were identified but these data demonstrate the ease with dual-
function screening can be performed. (PDF 1328 kb)
Abbreviations
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